BioSpace News Archive

Lucid Diagnostics Inc. today announced that the Company will host a business update conference call and webcast on Monday, November 14, 2022, at 4:30 PM EDT.

Albireo Pharma, Inc. announced the completion of patient enrollment in the BOLD study, a global gold standard Phase 3 pivotal trial of Bylvay in 205 patients with biliary atresia over 24 months.

Minerva Neurosciences, Inc. today announced that it will release financial results and business updates for the third quarter of 2022 on Wednesday, November 9, 2022.

ProSomnus (“the Company”), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the ProSomnus EVO™ [PH] Sleep and Snore Device.

Processa Pharmaceuticals, Inc. announces today it will host a conference call and live webcast on November 8, 2022, at 4:30 p.m. EST to discuss its third quarter 2022 results and provide an update on its clinical pipeline.

CorMedix Inc. today announced that it will report its financial results for the third quarter ended September 30, 2022, before the market open on Thursday, November 10, 2022, and will host a corporate update conference call at 8:30am Eastern Time.

ABVC Biopharma, Inc. today announced that the Cedars-Sinai Medical Center (CSMC, West Hollywood CA) Institutional Review Board (IRB) has approved their institution joining the Phase I study of ABV-1601 for treating depression in cancer patients.

SELLAS Life Sciences Group, Inc. today provides webcast information for its virtual investor event on November 14, 2022, at 8:30 a.m. ET. at which the Company will provide an update on its Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia.

Evoke Pharma, Inc. today announced that the Company is scheduled to release its third quarter on Wednesday, November 9, 2022, after the market closes.

Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced that Brazil’s health regulatory agency, ANVISA, the equivalent of the US Food and Drug Administration, has given an approval to market Sofwave’s™ SUPERB device in Brazil.